On Monday, Truist Securities maintained a Buy rating and a $33.00 price target on shares of Exelixis (NASDAQ:EXEL). This follows the recent announcement of a collaboration between Exelixis and Merck (NYSE:MRK) to conduct clinical trials for the treatment of certain types of cancer. The companies will work together to evaluate the combination of Exelixis' tyrosine kinase inhibitor zanzalintinib and Merck's anti-PD-1 therapy KEYTRUDA in a phase 3 pivotal trial aimed at treating patients with head and neck squamous cell carcinoma (HNSCC).
Additionally, the partnership will explore the use of zanzalintinib with WELIREG, Merck's oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, in a phase 1/2 trial and two phase 3 pivotal trials for patients with renal cell carcinoma (RCC).
The analyst from Truist Securities expressed a positive outlook on the collaboration, highlighting the due diligence performed by Merck in forming the deal. The analyst's comments suggest confidence in the potential of zanzalintinib, indicating that the drug is believed to be a safer and possibly more effective alternative to Cabozantinib, known commercially as Cabo. The anticipated superior safety and efficacy profile of zanzalintinib could lead to increased revenue potential for Exelixis.
The collaboration between Exelixis and Merck represents a significant step in the development of treatments for HNSCC and RCC. Exelixis' investigational drug zanzalintinib is expected to complement Merck's existing cancer therapies, potentially offering enhanced treatment options for patients suffering from these challenging diseases.
The strategic partnership will enable both companies to leverage their respective expertise in oncology drug development. The commencement of the trials will mark the beginning of a rigorous evaluation process, with the aim of establishing the safety and efficacy of the drug combinations for patients with HNSCC and RCC.
In other recent news, Exelixis and Merck have embarked on a clinical development collaboration focusing on cancer drug trials. The partnership aims to explore the combination of Exelixis' investigational tyrosine kinase inhibitor (TKI) zanzalintinib with Merck’s anti-PD-1 therapy KEYTRUDA in trials for head and neck squamous cell carcinoma and renal cell carcinoma. Merck has also recently completed the acquisition of CN201 from Curon Biopharmaceutical, a novel bispecific antibody, for approximately $750 million.
Furthermore, Merck's Phase 3 KEYNOTE-689 trial showed significant improvement in event-free survival for patients treated with KEYTRUDA in combination with standard radiotherapy. Analyst firms TD Cowen and BMO Capital Markets have maintained their Buy and Outperform ratings on Merck, respectively. TD Cowen noted Merck's favorable position among its pharmaceutical peers, while BMO Capital Markets highlighted the strong performance of Merck's investigational therapy, ivonescimab.
Lastly, Truist Securities has revised its price target for Merck from $143.00 to $132.00, following the acquisition of CN201 and an increase in projected research and development expenses.
InvestingPro Insights
To complement the article's focus on Merck's collaboration with Exelixis in cancer treatment development, let's examine some key financial metrics and insights for Merck (NYSE:MRK) from InvestingPro.
Merck's financial health appears robust, with a market capitalization of $278.47 billion and a revenue of $62.48 billion over the last twelve months as of Q2 2024. The company's revenue growth of 7.15% during this period indicates steady expansion, which aligns with its ongoing investments in research and development, including collaborations like the one with Exelixis.
An InvestingPro Tip highlights that Merck has raised its dividend for 13 consecutive years, demonstrating a commitment to shareholder returns. This consistent dividend growth, coupled with a current dividend yield of 2.81%, may appeal to investors looking for stable income alongside potential growth from new drug developments.
Another relevant InvestingPro Tip notes that Merck is a prominent player in the Pharmaceuticals industry. This position strengthens the significance of its collaboration with Exelixis, as it brings substantial resources and expertise to the partnership.
For readers interested in a deeper analysis, InvestingPro offers 8 additional tips for Merck, providing a more comprehensive view of the company's financial position and market standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.